IQVIA Holdings Inc
Research IQVIA Holdings Inc (IQV) on Bullrun: valuation model: 19.2% overvalued, market cap USD 43.16B, P/E 32.5. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIQV
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Valuation signal19.2% overvalued
- Market capUSD 43.16B
- P/E32.5
- Financial periodQ2 2026
- RevenueUSD 4.37B
- Net incomeUSD 256.00M
- Free cash flowUSD 360.00M
- Gross margin32.9%
Valuation Snapshot
Bullrun's latest valuation model marks IQVIA Holdings Inc as 19.2% overvalued; latest market cap is USD 43.16B; P/E is 32.5.
Peer valuation comparison
Latest P/E is 32.52x versus a Healthcare sector median of 24.6x (32.2% above).
Latest P/E is 32.52x versus a United States median of 23.85x (36.4% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 16.31B | USD 1.36B | USD 2.05B | 33.3% | 7.84 | USD 1.98B | USD 15.72B | USD 6.50B |
| FY2024 | USD 15.41B | USD 1.37B | USD 2.11B | 34.9% | 7.49 | USD 1.70B | USD 13.98B | USD 6.07B |
| FY2023 | USD 14.98B | USD 1.36B | USD 1.50B | 35.0% | 7.29 | USD 1.38B | USD 13.67B | USD 6.11B |
| FY2022 | USD 14.41B | USD 1.09B | USD 1.59B | 34.9% | 5.72 | USD 1.22B | USD 12.75B | USD 5.77B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 43.16B | 32.5 | n/a | n/a |
| 2025 | 2025-12-31 | USD 38.23B | 28.7 | n/a | n/a |
| 2024 | 2024-12-31 | USD 34.61B | 26.2 | n/a | n/a |
| 2023 | 2023-12-29 | USD 42.23B | 38.8 | n/a | n/a |
| 2022 | 2022-12-30 | USD 38.06B | 33.3 | n/a | n/a |
| 2021 | 2021-12-31 | USD 53.78B | 57.0 | n/a | n/a |
About IQVIA Holdings Inc
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services;
ETFs that hold IQVIA Holdings Inc
IQVIA Holdings Inc is one of the ten largest holdings of 10 ETFs that investors in Europe can buy. The 8 most traded of them:
| ETF | Weight | TER |
|---|---|---|
| Xtrackers S&P 500 Equal Weight UCITS ETF 1C | 0.25% | 0.15% |
| iShares Healthcare Innovation UCITS ETF USD (Acc) | 1.75% | 0.40% |
| Xtrackers S&P 500 Equal Weight UCITS ETF 2C EUR Hedged | 0.25% | 0.30% |
| Invesco S&P 500 Equal Weight Index ETF Acc | 0.25% | 0.20% |
| Xtrackers S&P 500 Equal Weight UCITS ETF 2D | 0.25% | 0.15% |
| Invesco S&P 500 Equal Weight Index ETF Inc | 0.27% | 0.20% |
| L&G Healthcare Technology & Innovation ETF USD Acc | 2.11% | 0.49% |
| VanEck Morningstar US SMID Moat UCITS ETF A Acc | 1.77% | 0.49% |
Compare every fund on the same index:
Related stock research
Other Healthcare stocks
Frequently asked questions
Is IQVIA Holdings Inc overvalued or undervalued?
Bullrun's valuation model currently marks IQVIA Holdings Inc as 19.2% overvalued.
What is IQVIA Holdings Inc's market cap?
IQVIA Holdings Inc's market capitalization is USD 43.16B.
What is IQVIA Holdings Inc's P/E ratio?
IQVIA Holdings Inc's price-to-earnings (P/E) ratio is 32.5.
What does IQVIA Holdings Inc do?
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.